Skip to the page

Data / Form D filings / Merge Bio Therapeutics Corp

Merge Bio Therapeutics Corp: Form D filing

Merge Bio Therapeutics Corp, a company in Cambridge, MA, filed a Form D with the SEC in 2025. The latest, on September 17, 2025, reports $5 million sold of a $15 million offering to 1 investor.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
1 KENDALL SQUARE, BUILDING 200, Cambridge, MA, 02139
Phone
(617) 286-2631
Industry
Other
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2025
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2086124

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Sep 17, 2025New notice$14,999,979$4,999,998$9,999,9811Aug 26, 2025sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Mark LipsteinPromoter
Steve LiapisDirector
Clinton HansenExecutive Officer, Promoter
Elias QuijanoDirector
Wesley WongExecutive Officer, Director, Promoter
Darren YangPromoter

Other companies in Massachusetts that filed recently

Every Form D from the week of Sep 15, 2025 · All recent filings in Massachusetts · All recent Other filings

Read from SEC EDGAR. Amount sold is what Merge Bio Therapeutics Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.